Navigation Links
DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Company's Scientific Advisory Board
Date:6/3/2008

LA JOLLA, Calif., June 3 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, today announced that Herbert A. Fritsche, Ph.D., has joined DermTech's Scientific Advisory Board. Dr. Fritsche is Professor and Chief of Clinical Chemistry at M.D. Anderson Cancer Center and one of the world's experts in the development and validation of cancer diagnostics for early disease detection and in the fast-growing area of translational research, moving research into clinical practice.

"We are honored that Dr. Fritsche is joining DermTech's Scientific Advisory Board and we are delighted to welcome him to the company," said George Schwartz, CEO, DermTech. "Dr. Fritsche has been with M.D. Anderson for almost 40 years and is one of the pioneers of today's molecular diagnostic assays for cancer detection and predicting drug response. His expertise will clearly be a major asset to DermTech as we are moving forward at an accelerated pace to develop our first product for the non-invasive early detection of melanoma."

"I am very pleased to become a member of DermTech's SAB and assist the company as it continues to optimize its novel melanoma assay and develops additional diagnostics using its "tape stripping" technology for the early detection of disease," said Herbert A. Fritsche, Ph.D. "This is an exciting time in medicine - in the field of cancer, I predict that within 10 years and maybe less, no major treatment decisions will be made without first consulting a laboratory test. I am looking forward to applying my experience to what I believe will be the next-generation approach to improved cancer detection."

Dr. Fritsche's career at M.D. Anderson includes some of the earliest work in translational research including the development of blood and tissue tests for protein tumor markers (CEA, AFP, HCG, LDH, B2M, estrogen and progesterone receptors), more recently, tests for circulating DNA (promoter regions of tumor suppressor genes for prostate cancer detection), urine mRNA survivin for bladder cancer detection and circulating tumor cell assays for establishing prognosis of patients with metastatic cancers.

Dr. Fritsche received his B.S. from the University of Houston (Chemistry), and M.S. and Ph.D. from Texas A & M University. Additionally, as Captain, Medical Service Corps, he completed a two-year assignment at the First US Army Medical Laboratory at Ft. Meade, MD before joining the faculty of the University of Texas MD Anderson Cancer Center.

About DermTech:

Headquartered in La Jolla, California, DermTech International is focused on the development and validation of molecular tests using specimens obtained from the skin. The company's proprietary Epidermal Genetic Information Retrieval (EGIR(TM)) technology is in clinical studies to evaluate its potential as a non-invasive diagnostic for melanoma and other major diseases. It is also being studied in the context of tracking treatment efficacy for a variety of dermatologic and other conditions, including the effects of drugs on skin at the molecular level in advance of observable clinical results. DermTech is actively pursuing research using EGIR(TM) and its applications in the areas of melanoma, prostate cancer and various skin disorders, such as psoriasis. For additional information visit http://www.dermtech.com.

Contacts:

DermTech

George Schwartz, CEO

858.450.4222

For DermTech

Jennifer Larson

415.409.2729

jlarson@labfive.com


'/>"/>
SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Abt Associates Names Richard Small Vice President and Chief Financial Officer
6. Premier Research Names Anthony Faragasso, MD as Executive Director and Global Head of Medical Management and Safety
7. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
8. Gene Network Sciences Names New CSO and Announces New Scientific Advisory Board
9. RiverVest Venture Partners(R), a St. Louis-Based Venture Capital Firm Focusing on Life Sciences, Closes on Fund II, Names John P. McKearn, Ph.D., Venture Partner
10. Codexis Names David Anton VP Bioindustrials R&D
11. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech Venture ... sector at their fourth annual Conference where founders, investors, innovative practitioners and collaborators ... ELEVATE pitch competition showcasing early stage digital health and med tech companies. , ...
(Date:10/5/2017)... ... ... LabRoots , the leading provider of educational and interactive virtual events ... cancer research with a month-long promotion supporting the advancement of breast cancer research with ... promo code PinkRibbon to get 10 percent off their purchase of every the “Cancer ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
Breaking Biology News(10 mins):